Association between quality of life and clinical outcome in women with advanced epithelial ovarian cancer receiving chemotherapy with concurrent and maintenance bevacizumab: results from a prospective multicenter phase 3 NRG Oncology/GOG trial

Phippen, Neil

Association between quality of life and clinical outcome in women with advanced epithelial ovarian cancer receiving chemotherapy with concurrent and maintenance bevacizumab: results from a prospective multicenter phase 3 NRG Oncology/GOG trial

Monday, March 30, 2015: 3:32 PM

International Ballroom (Hilton Chicago)

N. T. Phippen¹, B. A. Davidson², S. Wolf², G. Samsa², D. Cella³, L. J. Havrilesky², R. A. Burger⁴, A. A. Secord², B. J. Monk⁵ and C. A. Leath III⁶
¹Walter Reed National Military Medical Center, Bethesda, MD, ²Duke University Medical Center, Durham, NC, ³Northwestern University, Chicago, IL, ⁴University of Pennsylvania, Philadelphia, PA, ⁵University of Arizona Cancer Center, Phoenix, AZ, ⁶University of Alabama at Birmingham, Birmingham, AL

2015 Annual Meeting on Women's Cancer®

March 26 - 31, 2015

Navigation

Association between quality of life and clinical outcome in women with advanced epithelial ovarian cancer receiving chemotherapy with concurrent and maintenance bevacizumab: results from a prospective multicenter phase 3 NRG Oncology/GOG trial